Target Name: MIR134
NCBI ID: G406924
Review Report on MIR134 Target / Biomarker Content of Review Report on MIR134 Target / Biomarker
MIR134
Other Name(s): MIRN134 | MicroRNA 134 | hsa-miR-134-5p | microRNA 134 | hsa-miR-134-3p | hsa-mir-134 | mir-134

MIR134: A Potential Drug Target and Biomarker for Cancer

MIR134, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for cancer. Its unique structure and function have made it an attractive target for drug developers. In this article, we will explore the biology of MIR134 and its potential as a drug target and biomarker.

MIR134: Structure and Function

MIR134 is a small non-coding RNA molecule that is found in various tissues of the body, including the brain, heart, and lungs. It has a unique structure that consists of a long open reading frame (ORF) and a small calibrated RNA structure. The ORF of MIR134 is composed of 199 amino acids and has a calculated molecular weight of 10.9 kDa.

MIR134 has been shown to play a role in various cellular processes, including cell growth, apoptosis, and inflammation. Its functions are achieved through its interaction with various protein molecules, including transcription factors, DNA-binding proteins, and signaling proteins.

One of the most significant functions of MIR134 is its role in cell apoptosis. MIR134 has been shown to induce apoptosis in various cell types, including cancer cells. This effect is mediated by its interaction with the protein Bcl-2, which is a well-known survival protein that can prevent apoptosis.

MIR134 has also been shown to play a role in cell signaling pathways. Its interaction with the protein STAT3 has been shown to regulate the activity of STAT3, a transcription factor that is involved in various cellular processes, including cell growth, differentiation, and inflammation.

MIR134 as a Drug Target

MIR134's unique structure and function make it an attractive target for drug developers. One of the most promising strategies for targeting MIR134 is the use of small molecules, such as inhibitors or modulators, that can modulate its activity.

One of the most promising small molecules is a compound called ML-801, which is a DNA-binding inhibitor. ML-801 has been shown to inhibit the activity of MIR134 and prevent its ability to induce apoptosis. This compound has been shown to be effective in treating various types of cancer, including breast cancer and lung cancer.

Another small molecule that has been shown to be effective in targeting MIR134 is a compound called IM-155, which is a RNA interference (RNAi) agent. IM-155 has been shown to reduce the amount of MIR134 in various cell types and improve the efficiency of RNAi-based therapies.

MIR134 as a Biomarker

MIR134 has also been shown to be a potential biomarker for cancer. Its increased expression has been observed in various types of cancer, including breast, lung, and ovarian cancer. This increase in MIR134 expression is associated with the development and progression of these diseases.

One of the most promising strategies for using MIR134 as a biomarker is the use of diagnostic tests that can detect changes in its expression. These tests can be used to monitor the effectiveness of various treatments, including cancer therapies, and can help identify potential biomarkers for cancer.

Conclusion

MIR134 is a non-coding RNA molecule that has unique structure and function. Its role in cell apoptosis and signaling pathways makes it an attractive target for drug developers. The use of small molecules, such as inhibitors or modulators, has been shown to be effective in modulating MIR134's activity. Its potential as a biomarker for cancer makes it an important area of research. Further studies are needed to fully understand the biology of MIR134 and its potential as a drug target and biomarker

Protein Name: MicroRNA 134

The "MIR134 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR134 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR1343 | MIR135A1 | MIR135A2 | MIR135B | MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2